Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group

Critical Reviews in Oncology/Hematology

Volumn 91, Issue 1, 2014, Pages 35-46

  Sodergren, Samantha C ^a   White, Alice ^a   Efficace, Fabio ^b   Sprangers, Mirjam ^c   Fitzsimmons, Deborah ^d   Bottomley, Andrew ^e   Johnson, Colin D ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Health Outcome Research Unit   (Italy)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d SWANSEA UNIVERSITY   (United Kingdom)

^e EORTC DATA CENTER   (Belgium)

Author keywords

Gastrointestinal stromal tumour; Imatinib; Side effects; Sunitinib; Symptoms; Tyrosine kinase inhibitors

Indexed keywords

IMATINIB; SUNITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMAL FECES; ALLERGY; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASCITES; BACKACHE; BLISTER; BURNING MOUTH SYNDROME; CANCER CHEMOTHERAPY; CEREBROVASCULAR ACCIDENT; CHILL; CLINICAL EFFECTIVENESS; CONFUSION; CONJUNCTIVITIS; CONSTIPATION; COUGHING; DEHYDRATION; DEPRESSION; DERMATITIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPHAGIA; DYSPNEA; EMPHYSEMATOUS CHOLECYSTITIS; ENDOCRINE DISEASE; EPIPHORA; EPISTAXIS; ESOPHAGITIS; EYE EDEMA; EYE REDNESS; FACE EDEMA; FAINTNESS; FATIGUE; FEVER; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; GYNECOMASTIA; HAIR DISEASE; HAND FOOT SYNDROME; HEADACHE; HEARING DISORDER; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HEMATOLOGIC DISEASE; HOARSENESS; HUMAN; HYPERSALIVATION; HYPERTENSION; HYPOTENSION; INDIGESTION; INFECTION; INTESTINAL DYSMOTILITY; INTESTINE PERFORATION; IRRITABILITY; KIDNEY DISEASE; LEUKOCYTOSIS; LEUKOPENIA; LIVER HEMORRHAGE; LOOSE FECES; LOSS OF APPETITE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MEMORY DISORDER; METABOLIC DISORDER; MOUTH DISEASE; MOUTH PAIN; MUCOSA INFLAMMATION; MUSCLE SPASM; MYALGIA; NAUSEA; NECK PAIN; NEUTROPENIA; ORAL MUCOSITIS; PARESTHESIA; PERITONITIS; PIGMENT DISORDER; PLEURA EFFUSION; PLEURAL PAIN; PNEUMATOSIS INTESTINALIS; PNEUMONIA; POLLAKISURIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRURITUS; QT PROLONGATION; RASH; RESPIRATORY FAILURE; REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SKIN BLEEDING; SKIN DISCOLORATION; SKIN DISEASE; SKIN MANIFESTATION; SKIN TINGLING; SLEEP DISORDER; STOMACH ANTRUM VASCULAR ECTASIA; STOMATITIS; SWEAT GLAND DISEASE; SYSTEMATIC REVIEW; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROID DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VOMITING; WEAKNESS; WEIGHT REDUCTION; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; EUROPE; GASTROINTESTINAL STROMAL TUMORS; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; EUROPE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUALITY OF LIFE;

EID: 84901609051     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.01.002     Document Type: Review

References (58)

1. Miettinen M., Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006, 130:1466-1478.
2. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
3. D'Amato G., Steinert D.M., McAuliffe J.C., Trent J.C. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005, 12:44-56.
4. Blanke C., Joensuu H., Demetri G., et al. Outcome of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate: four-year follow-up of a phase II randomized trial. ASCO Gastrointestinal Cancers Symposium 2006.
5. Joensuu H., Hohenberger P., Corless C. Gastrointestinal stromal tumour. Lancet 2013, [Online]. 10.1016/S0140-6736(13)60106-3.
6. DeMatteo R., Ballman K., Antonescu C. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373(9669):1097-1104.
7. Joensuu H., Trent J., Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2011, 37(1):75-88. 10.1016/j.ctrv.2010.04.008.
8. Joensuu H., Eriksson M., Sundby Hall K., et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012, 307(12):1265-1272.
9. Wong D., Lupton S., Bhatt L., et al. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham cancer network experience. Clin Oncol 2008, 20(7):517-522.
10. Zhu J., Yang Y., Zhou L., Jiang M., Hou M. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome. BMC Cancer 2010, 10(199). 10.1186/1471-2407-10-199.
11. Blanke C., Rankin C., Demetri G., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008, 26(4):626-632.
12. Demetri G.D., Von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347(7):472-480.
13. Blay J., Le Cesne A., Ray-Coquard I., Al E. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007, 25(9):1107-1113.
14. Verweij J., Casali P., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364(9440):1127-1134.
15. Wolter P., Schoeffski P. Targeted therapies in the treatment of GIST: adverse events and maximising the benefits of sunitinib through proactive therapy management. Acta Oncol 2010, 49(1):13-23.
16. Verweij J., Van Oosterom A., Blay J. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003, 39(14):2006-2011. 10.1016/S0959-8049%2802%2900836-5.
17. Van Glabbeke M., Verweij J., Casali P., et al. Prognostic factors of toxicity and efficacy in patients with gastro-intestinal stromal tumors (GIST) treated with imatinib: a study of the EORTC-STBSG, ISG and AGITG. Proc Am Soc Clin Oncol 2003, 818. http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/270/CN-00486270/frame.html [abstract].
18. Agata N., Ueno N., Houzawa H., et al. Interim safety results from the all cases post-marketing study (PMS) of sunitinib in 1,027 Japanese patients with renal cell carcinoma (RCC) or gastrointestinal stromal tumor (GIST). J Clin Oncol 2011, 29(Suppl.):e31513.
19. Yoon D., Ryu M., Ryoo B., et al. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. Invest New Drugs 2012, 30(2):819-827.
20. Fromme E., Eilers K., Mori M., Hsieh Y., Beer T. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 2004, 22(17):3485-3490.
21. Basch E., Iasonos A., McDonough T., Al E. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 2006, 7(11):903-909.
22. National Cancer Institute, U.S.Department of Health and Human Services, Division of Cancer Control and Population Sciences Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) 2012, [accessed 28.05.12].
23. Blay J. Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann Oncol 2010, 21(2):208-215.
24. Essat M., Cooper K. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. Int J Cancer 2011, 128(9):2202-2214.
25. Younus J., Verma S., Franek J., Coakley N. Sunitinib malate for gastrointestinal stromal tumour n imatinib mesylate-resistant patients: recommendations and evidence. Curr Oncol 2010, 17(4):4-10.
26. Pisters P., Patel S. Gastrointestinal stromal tumors: current management. J Surg Oncol 2010, 102(5):530-538.
27. Quek R., George S. Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. Biologics 2010, 4:19-31.
28. Dissemination CfRa. Systematic reviews: CRD's guidance for undertaking reviews in health care [Internet].
29. Moher D., Liberati A., Tetzlaff J., Altman D. The PG preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(7):e1000097. 10.1371/journalpmed1000097.
30. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344(14):1052-1056.
31. van Oosterom A., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358(9291):1421-1423.
32. Weise A., Liu C.Y., Shields A. Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine. Ann Pharmacother 2009, 43(4):761-766.
33. Bar-Sela G., Kedem E., Hadad S., et al. Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor. Jpn J Clin Oncol 2010, 40(2):163-165.
34. Jarkowski A., Hare R., Francescutti V., Wilkinson N., Khushalani N. Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor. Anticancer Res 2011, 31(10):3429-3432.
35. Quek R., Morgan J., George S., et al. Small molecule tyrosine kinase inhibitor and depression. J Clin Oncol 2009, 27(2):312-313.
36. Montemurro M., Schöffski P., Reichardt P., et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009, 45(13):2293-2297.
37. Pfizer Inc. Safety and effectiveness of daily dosing with sunitinib or imatinib in patients with gastrointestinal stromal tumors. ClinicalTrials.gov Identifier NCT00372567. ClinicalTrials.gov; 2006. Available from: [accessed April 2013]. http://clinicaltrials.gov/.
38. Demetri G., van Oosterom A., Garrett C., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368(9544):1329-1338.
39. Watanabe K., Otsu S., Morinaga R., et al. Vesicocutaneous fistula formation during treatment with sunitinib malate: case report. BMC Gastroenterol 2010, 10(128).
40. de Lima Lopes G., Rocha Lima C.M. Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib. Pharmacotherapy 2007, 27(5):775-777.
41. Haap M., Gallwitz B., Thamer C., et al. Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor. J Endocrinol Invest 2007, 30(8):688-692.
42. Azribi F., Razak A., Dildey P., Adam J., Wilsdon J., Verrill M. Imatinib in gastrointestinal stromal tumour: Northern Cancer Network experience. Ecancermedicalscience 2009, 3:162.
43. Van Glabbeke M., Verweij J., Casali P., et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 2006, 42(14):2277-2285.
44. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368(9544):1329-1338.
45. Dagher R., Cohen M., Williams G., et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Can Res 2002, 8(10):3034-3038.
46. Chen Y., Yeh C., Cheng C., et al. Sunitinib for taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World J Gastroenterol 2011, 17(16):2113-2119.
47. Dos Reis Simoes Da Silva F., Burgos Pego P., Henriques Vendrell M., et al. Posterior reversible encephalopathy syndrome and anti-angiogenic agents: a case report. Neuro-Ophthalmology 2011, 35(1):32-37.
48. Park I., Ryu M., Sym S., et al. Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor. Jpn J Clin Oncol 2009, 39(2):105-110.
49. Gong J., Li J., Gao J., Sun N., Shen L. Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients. World J Gastroenterol 2012, 18(7):698-703.
50. Nishida T., Shirao K., Sawaki A., et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol 2008, 13(3):244-251.
51. Zalcberg J., Verweij J., Casali P., et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. Eur J Cancer 2005, 41(12):1751-1757.
52. Cohen M., Farrell A., Justice R., Pazdur R. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Oncologist 2009, (2):174-180. Available from: http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/894/CN-00705894/frame.html [Internet].
53. Kamba T.M.D. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96:1788-1795.
54. Ramsden J. Angiogenesis in the thyroid gland. J Endocrinol 2000, 166:475-480.
55. Noens L., van Lierde M.A., De Bock R., Verhoef G., Zachee P., Berneman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
56. Naranjo C., Busto U., Sellers E., Sandor P., Ruiz I., Al R.E.E. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
57. Severino G., Chillotti C., De Lisa R., Del Zompo M., Ardau R. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother 2005, 39(1):162-164. Probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
58. Rutowski P., Ruta W. Emergency surgery in the era of moleculartreatment of solid tumours. Lancet Oncol 2009, 10(2):157-163.